Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
about
Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)Caspase-8 as a regulator of tumor cell motilityDNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review)Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.H-Ras regulation of TRAIL death receptor mediated apoptosisTRAIL in cancer therapy: present and future challenges.The TRAIL of oncogenes to apoptosis.Death receptor 5 expression is inversely correlated with prostate cancer progression.Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancerEpigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cellsRegulating TRAIL receptor-induced cell death at the membrane : a deadly discussionTargeted ovarian cancer treatment: the TRAILs of resistance.On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.Regulation in the targeting of TRAIL receptor 1 to cell surface via GODZ for TRAIL sensitivity in tumor cellsTNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist.TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects.Telomere-homologous G-rich oligonucleotides sensitize human ovarian cancer cells to TRAIL-induced growth inhibition and apoptosis.Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer.Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Prostate Cancer Cells after Treatment with Xanthohumol-A Natural Compound Present in Humulus lupulus L.Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.TRAIL receptor signaling and therapeutics.Naturally occurring, tumor-specific, therapeutic proteins.TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.The three Rs along the TRAIL: resistance, re-sensitization and reactive oxygen species (ROS).Cancer development, progression, and therapy: an epigenetic overview.DNA methylation and apoptosis resistance in cancer cellsRestoring TRAIL mediated signaling in ovarian cancer cells.Meta-analysis demonstrates no association between p16 ink4a promoter methylation and epithelial ovarian cancer.Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities.Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.Upregulation of c-FLIP-short in response to TRAIL promotes survival of NSCLC cells, which could be suppressed by inhibition of Ca2+/calmodulin signalingMethylation status of TUSC3 is a prognostic factor in ovarian cancer.Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway.Dual role of TMS1/ASC in death receptor signaling.
P2860
Q26859211-47552A2D-ABC1-4F1C-B6BA-6811C66127CBQ26996626-5EF3542D-775D-4C08-94E8-2C671290E095Q33799002-25398726-A7D0-4295-A3C7-C2B24DA0E4CFQ33999606-1060B14D-6885-4591-B9B5-E90624CEAE39Q34104161-B2814F51-D257-4F6C-A198-86351D63AB22Q34291312-AD4E333F-B6FE-4695-AF7E-77C471C20F0BQ34354511-92284E62-78C7-4E2C-B1E2-2CE8BF787BD4Q34426868-1454E92D-8168-4A07-A979-91CC98C8565AQ34711457-B4BD56DF-A41C-4C0F-B335-73AB845A6B08Q35117949-7175D895-DF6D-424B-A512-0C95DB2D6F22Q35480734-1BE6961E-C748-4FBB-B973-B311D1B4BCF6Q35609438-58CE0433-0583-4B12-9E03-C1F47F800C2FQ35853714-EFAB770A-F0E9-4B3D-8E58-FAA05D8B74B0Q36028494-2EFABFA3-31AF-4D1D-8BFE-BCB4461068DAQ36365504-208EC7FE-05CA-4237-8286-55FBE6FAADFCQ36388792-AFFD684D-5F8F-422F-952E-2A5C8AB2E01FQ36392814-BD8098F9-F316-4096-8B7D-08EF935AE106Q36731174-2E23C4DE-3A22-455E-AB01-A04DC6C08412Q36804432-7E080568-B25E-4DA7-ADBD-82A53B5D27F8Q36862798-7DA0A496-EE4B-4768-A2AD-DBF6A83A802AQ37000936-941822DE-7DCE-40F5-B535-83CDFAB960CCQ37050555-81A8F2E9-0C5B-4F95-B0F5-233FBA1EF9B5Q37114025-87B91348-506E-4B8A-9FC0-A899CAA043C9Q37287542-8EAB0891-DE46-423B-843A-C5FCA81D096CQ37299291-513A6C5C-88C1-4F94-A220-5CE5FC0B89F0Q37785559-07B1F2CC-2657-4F63-AB0C-2A5FE6090098Q37869260-A3830C4B-C6C8-4C34-9A9C-9F95F40CC9F1Q37972139-0355C63C-2637-44C6-8B3C-F16526EB7956Q38007570-14EFBEFF-0EFB-4BEC-8ECF-6F23CC7443F0Q38154977-1B12C7BC-4D97-4E97-ACF2-F2EB4DD45E2BQ38202821-A704EAAD-383A-4FB5-81A8-031484417807Q38230205-EE8C021D-1737-4238-A348-136391983BC2Q38374740-B124E095-0D25-454B-BA90-D6F21CE97E92Q38575137-4B1906D4-59B6-45D3-8E07-95B1773A828EQ38823727-26F62C52-0312-4484-92E9-2A58A49D8AEDQ39183627-EA4028DF-98D1-4CE3-9E31-39C9DEF65CCFQ39253858-5504D99B-D78F-4871-A9D8-8EB65DFE10E9Q39774780-E93D221F-D0D9-4234-8DEE-18413C0A9A93Q39912926-C670C510-19B6-45AA-BC31-ABC1ADB50CCCQ40277157-43C68C8C-52FC-48DA-AE18-3B6BD661724D
P2860
Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Contribution of epigenetic sil ...... resistance and ovarian cancer.
@en
type
label
Contribution of epigenetic sil ...... resistance and ovarian cancer.
@en
prefLabel
Contribution of epigenetic sil ...... resistance and ovarian cancer.
@en
P2093
P50
P1476
Contribution of epigenetic sil ...... resistance and ovarian cancer.
@en
P2093
Christoph Zielinski
Griet Haller
Ingrid Pribill
Max Roessler
Reinhard Horvat
Sandra Tomek
P304
P356
10.1158/1541-7786.MCR-04-0136
P577
2005-06-01T00:00:00Z